Kerendia's primary application is for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes [1][2]. It is also used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attack, and hospitalization for heart failure in adults with these conditions [3].
How does Kerendia work to protect the kidneys?
Kerendia, with the active ingredient finerenone, functions as a non-steroidal, selective mineralocorticoid receptor (MR) antagonist [4][5]. By blocking the overstimulation of MRs, finerenone helps to reduce inflammation and fibrosis in the kidneys and blood vessels, which are key drivers of CKD progression [6][7]. This mechanism counteracts the harmful effects of excess mineralocorticoid receptor activation that can occur in diabetes and kidney disease [5].
What clinical trials support Kerendia's effectiveness?
The efficacy of Kerendia was established in studies including the Finerenone in Reducing Kerendia and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease (FIDELIO-DKD) trial and the Finerenone Cross-Complimentary Study to Assess Renal Outcomes and Cardiovascular Events (férence) trial [1][8]. These trials demonstrated significant reductions in the composite endpoint of kidney function decline, kidney failure, and kidney-related death, as well as cardiovascular events [1][8].
When does Kerendia's patent protection expire?
The patent landscape for Kerendia involves multiple patents covering the composition of matter, methods of use, and manufacturing processes. DrugPatentWatch.com tracks these patents, which determine the period of market exclusivity [9]. Specific expiry dates for Kerendia's patents can be found on specialized drug patent tracking services.
What are the potential side effects of taking Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [3]. Patients should be monitored for potassium levels and kidney function during treatment [3][5].
How does Kerendia compare to other CKD treatments?
Kerendia offers a novel mechanism of action as a selective MR antagonist, distinguishing it from other CKD treatments which may include ACE inhibitors, ARBs, SGLT2 inhibitors, and diuretics [5][10]. While these other classes of drugs are also important in managing CKD and type 2 diabetes, Kerendia targets a different pathway involved in kidney damage [5][7].
What are the risks of elevated potassium levels with Kerendia?
Elevated potassium levels, or hyperkalemia, is a significant risk factor with Kerendia and can be serious if not managed [3][5]. Regular monitoring of serum potassium is crucial, and dose adjustments or temporary discontinuation of the medication may be necessary [3].
Can generic versions of Kerendia be developed?
The development of generic versions of Kerendia is contingent upon the expiration of its relevant patents [9]. Once patents expire, other pharmaceutical companies may be able to seek approval to manufacture and market generic equivalents.
Who manufactures Kerendia?
Kerendia is developed and manufactured by Bayer [1][2].
Where can I find more information on Kerendia's drug patents?
Information regarding drug patents for Kerendia, including potential expiry dates and patent challenges, can be accessed through dedicated resources like DrugPatentWatch.com [9].
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/kerendia
[2] https://www.drugpatentwatch.com/drugs/kerendia-drug-patent-expiration-date
[3] https://www.news-medical.net/drugs/Kerendia.aspx
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479015
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2027183
[6] https://www.karger.com/Article/FullText/505821
[7] https://pubmed.ncbi.nlm.nih.gov/33851787
[8] https://www.bayer.com/en/news-room/press-releases/press-release-detail/?id=8226
[9] https://www.drugpatentwatch.com/
[10] https://www.kidney.org/patients/treatment-options